Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Purchases 84,124 Shares of Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. purchased 84,124 shares of Artiva Biotherapeutics stock in a transaction that occurred on Wednesday, July 22nd. The shares were bought at an average cost of $9.93 per share, for a total transaction of $835,351.32. Following the transaction, the director directly owned 17,182,603 shares of the company’s stock, valued at $170,623,247.79. This represents a 0.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, July 24th, Ra Capital Management, L.P. acquired 41,319 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $9.99 per share, with a total value of $412,776.81.
• On Thursday, July 23rd, Ra Capital Management, L.P. bought 59,880 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.96 per share, with a total value of $596,404.80.
• On Tuesday, July 21st, Ra Capital Management, L.P. bought 120,582 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $9.55 per share, with a total value of $1,151,558.10.
• On Friday, July 10th, Ra Capital Management, L.P. bought 15,102 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.97 per share, for a total transaction of $135,464.94.
• On Monday, July 13th, Ra Capital Management, L.P. purchased 6,552 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.94 per share, for a total transaction of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. purchased 1,876 shares of Artiva Biotherapeutics stock. The stock was bought at an average price of $8.98 per share, for a total transaction of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. purchased 31,000 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. acquired 124,893 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. acquired 15,414 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. acquired 391,019 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.57 per share, for a total transaction of $3,351,032.83.

Artiva Biotherapeutics Stock Up 2.0%

ARTV stock opened at $10.53 on Wednesday. Artiva Biotherapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $14.53. The firm has a market cap of $260.30 million, a P/E ratio of -2.97 and a beta of 2.18. The company’s 50-day moving average price is $8.87 and its two-hundred day moving average price is $7.42.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Equities analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Institutional Trading of Artiva Biotherapeutics

A number of hedge funds have recently made changes to their positions in the company. Prelude Capital Management LLC bought a new stake in Artiva Biotherapeutics during the 3rd quarter worth approximately $41,000. Bank of America Corp DE raised its stake in shares of Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after acquiring an additional 11,190 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Artiva Biotherapeutics during the first quarter valued at $131,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Artiva Biotherapeutics during the fourth quarter worth $91,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Artiva Biotherapeutics during the first quarter worth $139,000.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on ARTV shares. Wedbush upped their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Needham & Company LLC reiterated a “buy” rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Finally, HC Wainwright raised their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Artiva Biotherapeutics currently has an average rating of “Moderate Buy” and an average price target of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.